Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Merck announced its investigational oral PCSK9 inhibitor, enlicitide, achieved a significant 59.7% placebo-adjusted reduction in LDL cholesterol in clinical trials, positioning it as a potential rival to injectable treatments like Amgen's Repatha and Regeneron's Praluent. This development could capture a substantial share of the estimated $47 billion cholesterol treatment market by 2033 by offering an easier-to-access oral alternative for patients, with Merck planning FDA submission in early 2026.

Analysis

Merck (MRK) announced compelling Phase 3 clinical trial results for its investigational oral PCSK9 inhibitor, enlicitide, at the American Heart Association annual meeting. The drug demonstrated a significant 59.7% placebo-adjusted reduction in LDL cholesterol, positioning it as a potent new treatment option. This efficacy is comparable to existing injectable PCSK9 inhibitors, which typically reduce LDL by 50-60%.

Enlicitide targets a substantial and growing cholesterol treatment market, estimated to reach nearly $47 billion by 2033. Its oral formulation offers a distinct advantage over current injectable rivals like Amgen's (AMGN) Repatha and Regeneron's (REGN) Praluent, which have historically faced adoption challenges despite strong recent sales growth (Repatha +40% YoY, Praluent +13% YoY in Q3). The oral route could significantly expand patient access, particularly for those unable to reach LDL goals with statins or who are statin-intolerant.

The drug exhibited a safety profile comparable to placebo, with 97% patient adherence to its fasted administration requirement. Merck plans to submit enlicitide for FDA approval in early 2026, aiming to capitalize on its potential as an "easier to access" and "profound LDL-lowering pill." This development represents a strategic move for Merck to capture a larger share of the cardiovascular market and could disrupt the current PCSK9 inhibitor landscape.

Key Decisions for Investors

• Monitor Merck's (MRK) regulatory progress for enlicitide, as FDA approval in early 2026 would significantly enhance its market position in the $47 billion cholesterol treatment sector.
• Assess the potential market disruption and competitive pressure on existing injectable PCSK9 inhibitor manufacturers like Amgen (AMGN) and Regeneron (REGN) due to enlicitide's oral convenience.
• Evaluate the long-term revenue potential for Merck, considering enlicitide's strong efficacy and safety profile, which could drive broad patient adoption and market penetration.